Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.
By P. Mcsweeney, D. Niederwieser, J. Shizuru, B. Sandmaier, A. Molina, D. Maloney, T. Chauncey, T. Gooley, U. Hegenbart, R. Nash and 14 more. Blood, 2001
1,373 citations recorded by the source corpus.
Subfields: Hematology, Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/e8dfe28dbcc2afab1290ce0f0a476d38271965f0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Oncology
Citations in the corpus
- Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease (2006, methodology): “Early: first remission or first chronic phase; late: after first remission and first chronic phase for hematological malignancies; CsA, cyclosporine; MTX, methotrexate; Pred, prednisolone; MMF, mycophenolate mofetil; Bu, busulfan; Cy, cyclophosphamide; TBI, total body irradiation; RIC, reduced inten”
- Drug therapy for acute myeloid leukemia. (2005, background): “52 Although the benefits of this strategy of nonmyeloablative HSCT is currently under investigation, 52,53 its ultimate role may be in older adults in first CR who are unable to tolerate standard conditioning regimens.”